Skip to Content

Malarone Pediatric (atovaquone / proguanil) Disease Interactions

There are 3 disease interactions with Malarone Pediatric (atovaquone / proguanil):

Major

Proguanil (Includes Malarone Pediatric) ↔ severe renal impairment

Severe Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Atovaquone and Proguanil tablets are contraindicated for prophylaxis of P. falciparum malaria in patients with severe renal impairment (creatinine clearance <30 mL/min). Use with caution for the treatment of malaria in patients with severe renal impairment, only if the benefits of the 3-day treatment regimen outweigh the potential risks associated with increased drug exposure. No dosage adjustments are needed in patients with mild (creatinine clearance 50 to 80 mL/min) or moderate (creatinine clearance 30 to 50 mL/min) renal impairment.

Moderate

Atovaquone (Includes Malarone Pediatric) ↔ gastrointestinal absorption

Moderate Potential Hazard, High plausibility. Applies to: Anorexia/Feeding Problems, Malabsorption Syndrome, Diarrhea

Oral bioavailability of atovaquone is limited under fasting conditions, but is increased approximately two-fold when administered with food. Patients with gastrointestinal disorders or eating difficulties may be more likely to have impaired absorption and, consequently, subtherapeutic levels of the drug. Alternative parenteral treatment should be considered for patients unable to achieve adequate plasma concentrations of atovaquone with oral administration.

References

  1. Rolan PE, Mercer AJ, Weatherley BC, Holdich T, Ridout G, Meire H "Investigation of the factors responsible for a food-induced increase in absorption of a novel antiprotozoal drug 566C80." Br J Clin Pharmacol 33 (1992): p534-5
  2. "Product Information. Mepron (atovaquone)." Glaxo Wellcome, Research Triangle Park, NC.
Moderate

Atovaquone (Includes Malarone Pediatric) ↔ liver disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Atovaquone may cause elevated liver function tests. In clinical trials, elevated serum alkaline phosphatase concentrations (> 2.5 times the upper limit of normal, or ULN) were reported in approximately 8% of patients, and elevations in serum ALT and AST (> 5 times ULN) were reported in 6% and 4% of patients, respectively. Increases in serum bilirubin has occurred rarely. Atovaquone also may undergo limited metabolism by the liver. Therapy with atovaquone should be administered cautiously in patients with severe hepatic impairment. Liver function tests should be performed periodically, and therapy withdrawn if significant elevations develop.

References

  1. "Product Information. Mepron (atovaquone)." Glaxo Wellcome, Research Triangle Park, NC.

Malarone Pediatric (atovaquone / proguanil) drug interactions

There are 118 drug interactions with Malarone Pediatric (atovaquone / proguanil)

Malarone Pediatric (atovaquone / proguanil) alcohol/food interactions

There is 1 alcohol/food interaction with Malarone Pediatric (atovaquone / proguanil)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide